HIGHLIGHTS
- who: Kathryn M. Thrailkill from the Johns Hopkins University, United States have published the Article: Emerging therapies for the treatment of rare pediatric bone disorders, in the Journal: (JOURNAL)
- what: Mechanism of action Burosumab-twza was developed for the treatment of FGF23 related hypophosphatemia; however, for the purpose of this review, its indication for the treatment of X-linked hypophosphatemia (XLH) in pediatric patients (but including adult treatment) will be discussed. Burosumab-twza binds to and inhibits the biological activity of FGF-23; as such, the drug is intended to impede FGF-23 signaling in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.